; on behalf of the Musculoskeletal Ultrasound Study Group of the Italian Society of Rheumatology Abstract Objective. To systematically review the role of musculoskeletal US in patients suffering from PsA or psoriasis (Pso) in terms of prevalence, diagnosis, prognosis, monitoring and treatment.
Introduction
PsA is a systemic inflammatory disease with articular and extra-articular features. In recent years, imaging is playing an increasingly important role in the differential diagnosis of and in monitoring treatment response in PsA. Recently, the EULAR recommendations for the use of imaging in the diagnosis and management of SpA advise the use of MRI and US for diagnosis, activity monitoring and structural change evaluation in peripheral SpA [1] . US demonstrated good accuracy, reliability and sensitivity to change in the assessment of various structures that may be involved in PsA, i.e. tendons, enthesis, synovium and bone [13] . In addition, the information given by US assessment can be integrated with that obtained by clinical examination, thus improving differential diagnosis (e.g. early seronegative polyarthritis), stratification of patients and therapeutic strategies in a treat-to-target (T2T) context [4, 5] . Currently, the utility of US in clinical practice is not yet supported by adequate evidence [6] ; therefore, reflecting the need to determine the role of US in diagnosis and prognostic stratification and to support prioritization of US studies in PsA, the Musculoskeletal Ultrasound Study Group of the Italian Society of Rheumatology decided to perform a systematic literature review (SLR) on the use of US in the management of PsA.
Methods
The Preferred Reporting Items for Systematic reviews and Meta-analyses were followed to design and report this review [7] . The most relevant areas of application of US in PsA and psoriasis (Pso) were identified, and prespecified inclusion criteria for each item were developed (supplementary Table S1 , available at Rheumatology Online).
Data sources and search
PubMed and Embase were searched, without time limits, up to 27 September 2015. The search strategy was developed based on search terms aiming at identifying studies including patients with PsA or Pso in which musculoskeletal US was performed. The search strategy is presented in supplementary Table S2 , available at Rheumatology Online. Abstracts of the ACR and EULAR congresses (2014 and 2015) were hand searched. Studies had to be published in English, and neither publication restrictions nor selection based on quality were applied.
Study selection
Studies of patients with suspected or confirmed PsA were included, including patients with mixed populations of arthritis (only some of the patients were diagnosed with PsA). Studies on patients with skin psoriasis without arthritis were also eligible for inclusion. US was considered as the index test/intervention; details on the comparators, outcomes and eligible study designs are shown in Table S1 . The reviewers (F.B., A.B., A.Z.) worked in pairs for each area of interest, independently screening titles and abstracts.
Data extraction and quality assessment Study characteristics and data were extracted using separate standardized forms for each area of interest. For diagnostic accuracy items, when possible, data were extracted as 2 Â 2 tables, and sensitivity, specificity, positive and negative likelihood ratios with 95% CIs were calculated. Pre-specified meta-analyses were not planned, due to the expected heterogeneity across studies. The hypothesis of heterogeneity was tested in the subgroup of studies assessing the performance of US in detecting elementary lesions. The risk of bias and methodological quality of the included studies were assessed with different tools, depending on study design. For diagnostic studies, the QUADAS-2 tool was used [8] ; for randomized controlled trials (RCTs) the risk of bias tool proposed by the Cochrane collaboration was used [9] , while for observational studies the NewcastleOttawa scale (NOS) was used [10] .
Results

Selected studies
Of the 365 studies produced by the PubMed and Embase searches, 71 studies met the criteria for inclusion. Furthermore 15 additional studies were included: 2 from the hand search and 13 from the 201415 abstracts of ACR and EULAR (Fig. 1) . Table 2 highlights high-quality studies on prevalence, diagnosis and prognosis.
Prevalence of US abnormalities in PsA and Pso
The search retrieved 56 studies examining the prevalence of US abnormalities in PsA (50/56 studies) and isolated Pso (6/50 studies) [1166] . The results are summarized in Table 1 and completely reported in supplementary Table  S3 , available at Rheumatology Online. Regarding the examined US abnormalities, synovitis, erosions and enthesopathy were often studied; less frequently, soft tissue inflammation (described as oedema) and/or power Doppler (PwD) peri-tendinous, were studied. The prevalence of the examined lesions had a wide range in the studies: 10100% for synovitis [22, 34, 48, 52, 55] ; 3794.5% for entheses thickness of the lower limbs [14, 15, 17, 24, 27, 30, 35, 36] ; and 10.852% for erosions [16, 34, 53, 55] . The sites examined were very variable, except for studies of US enthuses, in which the lower limbs were the most frequently studied. For entheses evaluation, the Glasgow Ultrasound Enthesitis Scoring System (GUESS) was the most commonly employed score [15, 17, 27, 41, 50, 59] , followed by the MAdrid Sonography Enthesitis Index (MASEI) score [12, 26] . Furthermore, two studies evaluated synovial contrast enhancement, with a prevalence in PsA of $30% [33, 55] . The risk of bias for all selected studies, assessed using the NOS, is reported in supplementary Table S3 , available at Rheumatology Online.
Making a diagnosis of PsA
Performance of US in the diagnosis of PsA and Pso
The search retrieved 23 studies, including a qualitative systematic review [67] , examining the performance of www.rheumatology.oxfordjournals.org US in diagnosing PsA [12, 17, 1921, 2631, 34, 37, 40, 42, 4547, 56, 58, 59, 68] . The results of the studies are summarized in Table S4 , available at Rheumatology Online, Fig. 2 , supplementary Figs S1 and S2, available at Rheumatology Online. The diagnostic performance of US was variable across studies; in particular, no study evaluated the overall performance of US in addition to clinical findings re diagnosing PsA, while most studies were focusing on single lesions. However, no study demonstrated an adequate performance for US variables, considered separately. The performance of US in detecting PsA was broadly variable among studies, with sensitivities ranging from 0.22 to 1.00 for enthesopathy, from 0.16 to 0.76 for synovial hypertrophy and from 0.14 to 0.58 for joint bone erosions. Also, sensitivities were extremely variable, ranging from 0.20 to 1.0 for enthesopathy, from 0 to 1.0 for synovial hypertrophy and from 0.40 to 1.0 for bone erosions. Most of the studies (22 out of 23) followed a cross-sectional casecontrol design, and the evaluation of the diagnostic performance of US was in many cases not the primary objective of the study. As expected, the studies were heterogeneous in terms of examined sites and reference standard, although clinical diagnosis or classification criteria were the only standards adopted. The risk of bias, assessed by the modified version of the QUADAS, was in general considered high for the items concerning patient recruitment, unclear for the items dealing with the index test and mostly low for the items covering the reference standard and the timing (supplementary Figure S3 , available at Rheumatology Online).
Performance of US in the diagnosis of PsA and Pso elementary lesions
The search retrieved 30 studies examining the performance of US in diagnosing PsA elementary lesions [11, 15, 16, 20, 2325, 30, 3234, 3739, 44, 45, 47, 48, 5153, 55, 57, 58, 63, 64, 6972] . The results of the studies are summarized in supplementary Table S5 , available at Rheumatology Online. The PsA elementary lesions evaluated were heterogeneous for type of lesions (e.g. synovial or extra-synovial features), anatomic structures and reference standard. The reference standard was clinical examination in 14 studies, MRI in 5, conventional radiography and arthroscopy in 3, and CT and histological evaluation in 1. Considering MRI as the reference standard, the sensitivity and specificity underwent wide variations depending on the examined anatomic structures and types of lesions; e.g. considering synovitis, sensitivity ranged from 0.49 to 0.94, while specificity ranged from 0.20 to 0.91 (supplementary Fig. S4 , available at Rheumatology Online). In the unique study using histopathology as the reference, the amount of PwD did not significantly associate with a global histopathological inflammatory score [44] , while for the single study comparing US with CT, a large proportion of bone lesions detected by US could be verified by CT [32] . The risk of bias, assessed by the modified version of the QUADAS, was in general considered high for the items concerning patients' recruitment, unclear for the items dealing with the reference standard and mostly low for the index test and flow and timing (supplementary Fig. S5 , available at Rheumatology Online). This subgroup of studies was used to test for the presence of heterogeneity across studies (supplementary Prognosis and follow-up
Role of US in defining PsA and Pso prognosis
The search retrieved 15 studies examining the role of US in defining PsA and Pso prognosis [11, 14, 23, 41, 49, 56, 59 , 7380], with only two having a prospective design [75, 80] . The results of the studies are summarized in supplementary Table S6 , available at Rheumatology Online. Several works, selected for this item, focused on target enthesis US in Pso patients revealing a high rate of subclinical inflammatory signs. Subclinical enthesitis, confirmed by a significantly higher Glasgow Ultrasound Enthesitis Scoring System (GUESS) score, was found more frequently in Pso compared with in healthy controls [14, 41, 73] , while only one study focused on the prevalence of subclinical synovitis in Pso [49] . There was only one prospective study, published by Tinazzi et al. in which GUESS scores of patients with Pso who developed PsA compared with those who did not develop PsA did not statistically differ. Furthermore, in the logistic regression analysis, baseline thickness of the quadriceps tendon was found to be an independent predictor of the development of PsA [75] . Moreover, the presence of PwD signal in enthesis, evaluated as entheseal-organ in Aydin et al. [14] and within 2 mm of bone insertion in Gutierrez et al. [41] , was found to be highly specific for psoriatic disease. The risk of bias for all selected studies, assessed using the NOS, is reported in supplementary Table S6 , available at Rheumatology Online.
Role of US in the follow-up of PsA and Pso
The search retrieved 15 studies exploring the role of US in PsA follow-up [18, 63, 69, 12, 8191] . The results are summarized in Table 3 . In several studies, US assessment was used to analyse the response to a standardized therapeutic approach with inhomogeneous US endpoints.
The comparison between articles is made difficult by the variability in definitions of elementary lesions and scoring systems, machine settings and image acquisition. Among the selected articles, five different scoring systems have been tested. The US Group of the Spanish Society of Rheumatology demonstrated that the power Doppler US (PDUS) examination of 14 peripheral entheses was able to monitor the 6 months therapeutic response in SpA patients [86] . The German US7 scores significantly reflected the therapeutic response of PsA patients, evaluating synovitis, tenosynovitis and erosions of small joints, whereas the sonography of large joints in Rheumatology (SOLAR score), used to evaluate synovitis and tenosynovitis of the large joints, was able to monitor the treatment response in a cohort of PsA patients [81, 88] . The Five Targets PwD for Psoriatic Disease score was the first score including all domains characterizing PsA (joint, tendon with synovial sheath, enthesis, skin and nail); those, one for each target area, showing the highest expression of PwD were selected for monitoring an anti-TNF therapy in PsA patients [90] . The Five Targets PwD for psoriatic disease score showed significant improvement during therapy, but it did not correlate with HAQ-modified for SpA. Finally, Ficjan et al. developed two US scores (PsA-Son22 and PsA-Son13) in a prospective study on 83 consecutive PsA patients; these scores explored joints, peri-articular structures and entheses. Both composite scores had sufficient sensitivity to show change, but the bilateral score (PsA-Son22) was more sensitive than the unilateral score for detecting PsA lesions [89] . The risk of bias, assessed using the NOS, the Preferred Reporting Items for Systematic reviews and Meta-analyses Checklist and the Cochrane diagnostic test Accuracy, was reported in Table 3 .
US to guide intra-articular interventions
The search retrieved four studies, including two randomized controlled trials, examining the role of US in guiding intra-articular interventions [9295] . Among the two RCTs, comparing blinded and US-guided injections, the results were controversial with respect to clinical outcome, but accuracy was better for US-guided procedures [94, 95] . In Sibbit et al. [95] , US-directed intra-articular injections were superior to palpation-guided methods in all therapeutic measures: absolute VAS pain scores for injection pain were 81% less, responder rates were increased by 38%, and non-responder rates were reduced by 34%. Conversely, in the study published by Cunnington et al. [94] , there was no statistically significant difference between US-guided and blind injections for any of the major outcome variables (e.g. VAS pain, function and stiffness) measured at 2 or 6 weeks. Only one study focused on tenosynovitis, and no study focused on enthesitis or bursitis [93] . The risk of bias, assessed by the Cochrane Collaboration's tool for intervention studies, is reported in supplementary Fig. S7 , available at Rheumatology Online.
Discussion
The usefulness of US in diagnosis, prognosis and followup of inflammatory arthritis in clinical practice is still a matter of debate, despite the evidence for higher sensitivity over clinical examination. Recently, an EULAR task force developed evidence-based recommendations on the use of imaging in the clinical management of RA and SpA [1, 96] , acknowledging the need of further extensive research in order to optimize the use of imaging in routine clinical practice. On this basis, and in order to identify and prioritize its research agenda in the field of PsA, the MSUS Study Group of the Italian Society of Rheumatology, decided to plan a SLR with the aim of highlighting the current state of knowledge. Currently, in early inflammatory arthritis, rheumatologists need supporting tools in order to strengthen diagnoses [97] . Among imaging modalities, US is the most attractive one, as it is less timeconsuming, safer, and readily and easily used. For this reason, an increasing number of studies about US for diagnosing PsA has recently been published. However, its use in clinical practice is still a matter of debate. In the SLR, the diagnostic performance of US was widely variable, and no study evaluated the overall performance of US in addition to clinical findings in diagnosing PsA. Moreover, most of the selected diagnostic studies www.rheumatology.oxfordjournals.org followed a cross-sectional casecontrol design, introducing a bias in patient selection (leading to an overestimation of the diagnostic performance of the index test). The ability of US to detect elementary lesions, which may support the diagnosis of PsA, is widely described in the literature. Considering the potential pathogenetic role of enthesis in PsA, US of entheses was (not surprisingly) most frequently used for diagnosis [11, 12, 15, 17, 2327, 30, 31, 38, 39, 42, 45, 46, 52, 59] . Furthermore, US was used to image synovitis, tenosynovitis, bursitis and erosions (and less frequently soft tissue and hand nails). Clinical examination was often the reference standard for both the diagnosis of PsA and of psoriatic elementary lesions. Only one study examined the performance of PwD in identifying synovitis, using histopathology as the gold standard, showing that a negative PwD in the synovium did not exclude the possibility of synovitis [44] . In axial SpA, imaging is a key component of classification criteria, mostly due to the absence of specific clinical symptoms [1] , while in the classification of peripheral inflammatory arthritis, its use is not mandatory. However, in early disease, imaging might play an important role in supporting diagnosis and directing the treatment. Regarding the differential diagnosis, studies seem to support the idea that PsA could be differentiated from RA by major extra-synovial involvement. Soft tissue inflammation, described as oedema and/or PwD peri-tendinous, could be a very distinctive sign of PsA, being absent in RA controls [34, 40, 45] . Fourniè et al. [34] highlighted major synovial involvement in RA compared with PsA (i.e. 100% vs 76%), and furthermore, the prevalence of erosions was lower in PsA than in RA [58, 60, 63] , even though this result was recently questioned by another study [45] . Moreover, the prevalence of features differed greatly between selected studies, mainly due to the heterogeneity of inclusion criteria, elementary lesion definitions and equipment. In addition, possible sources of bias mainly related to patient selection might have been present. With sooner the better being the ideal treatment strategy, the application of US in predicting the development of arthritis in Pso patients or in identifying PsA patients with poorer outcome, is of interest. Considering the importance of enthesitis as the key lesion in PsA, some studies focused on entheses of lower limbs in psoriatic disease (with or without arthritis), revealing an high rate of enthesopathy signs [14, 41, 73] , particularly for PwD activity. The results of the SLR supported the idea that entheseal PwD, rather than grey-scale (GS) changes, is a highly specific feature for PsA. However, the prognostic role of these lesions in the development of arthritis in Pso patients is not yet clear. There was only one prospective work by Tinazzi et al. [75] demonstrating that, in Pso patients, the baseline thickness of the quadriceps tendons was an independent predictor of PsA development, suggesting the need for further investigation in larger cohorts. Currently, in RA synovitis, tenosynovitis and bone marrow oedema appear to be predictors of radiographic progression and synonymous with disease activity [93, 98100] . To date, in PsA, US predictors of poorer outcome have not [101] , the potential role of US in monitoring disease activity has to be tested, in addition to clinical follow-up. The integration of US with clinical examination for stratifying patients and for deciding treatments in a T2T strategy also represents an interesting possibility. The SLR identified few US scores for monitoring disease activity in PsA patients. The German US7 score, developed in RA, was the first applied and was able to significantly reflect the therapeutic response of PsA patients, evaluating synovitis, tenosynovitis and erosions [81] . Focusing on large joints, the SOLAR score, was used to evaluate activity in a cohort of PsA and AS patients, and Schafer et al. concluded that it was a valuable tool [88] . Furthermore, the Group of the Spanish Society of Rheumatology demonstrated that the PDUS examination of 14 peripheral entheses was able to monitor the response of SpA patients during anti-TNF therapy, and (interestingly) the authors highlighted that the score may contribute to the development of a cumulative scoring system of combined elementary lesions [86] . Considering the clinical heterogeneity of PsA with different domains and peculiar sites involved, a dedicated US composite score is arguably necessary. First, Gutierrez et al.
[90] developed a PsA dedicated preliminary five-target score for the assessment of PsA patients during anti-TNF therapy. Later, Ficjan et al. [89] also proposed two PsA-specific US scores (PsASon-13 and PsASon-22) for monitoring disease activity in PsA. All these last three scores are original and interesting, but they are not applied in other series; thus, they remain preliminary scores, despite good sensitivity for the detection of inflammation and feasibility. Although there is extensive use in clinical practice, the superiority in terms of clinical outcome of US-guided injections over blinded injections remains doubtful in PsA, and further studies are needed in order to better define the efficacy of one over the other. US-guided injections were overall more accurate. Accordingly, Cunnington et al. recommended US-guided procedures in joints that were frequently injected inaccurately (e.g. shoulder, ankle, hip) and in order to reduce tissue necrosis or possible damage to surrounding tissues [94] . Thus, safety seems to be an advantage of US-guided injections. Although the SLR pointed up the importance and potential of US in the management of PsA and Pso, it also underlined the need for a large amount of research into optimizing the use of US in the diagnosis and monitoring of psoriatic disease in clinical practice. In particular, several gaps in the literature were underlined, as well as the presence of possible biases (such as in patient selection, the reference standard for diagnostic studies and randomization in interventional studies). In addition, since the presence of publication bias was not investigated, it cannot be excluded. Based on the evidence arising from the SLR, a research agenda has also been proposed ( 
